Affiliation:
1. Sağlık Bilimleri Üniversitesi
Abstract
Abstract
INTRODUCTION: To examine the ability of changes in optical coherence tomography angiography (OCTA) values to predict progression in the visual field (GA) and retinal nerve fiber layer (RNFL) in patients with glaucoma progression. METHODS: All patients in the glaucoma outpatient clinic of SBU Gülhane Medical Faculty between 2021–2023 underwent RNFL, 24:2 GA and simultaneous peripapillary OCT-A. 130 eyes that progressed were included in the study. Thinning of more than 5 µ in any quadrant in the RNFL or a decrease of more than 1 dB in the MD value in the visual field within 6 months was accepted as a progression criterion. The ability of changes in OCTA-RNFL and OCTA radial peripapillary capillary plexus (RPCP) analysis to predict progression in RNFL and GA was prospectively investigated. RESULTS: The mean age of the patients was 66.9 ± 11.8 years. There was progression in GA in 70 eyes and RNFL in 89 eyes between baseline and 6-month controls. The ability to predict the progression of the change in OCTA-RNFL in the superior, inferior, nasal, temporal and total quadrants was not sufficient (p = 0.55, 0.40, 0.84, 0.91, 0.39, respectively). Changes in OCTA-RNFL values failed to predict GA MD progression in the superior, inferior, nasal, temporal, and total quadrants (p = 0.40,0.11,0.24,0.44, and 0.10, respectively). The ability of the change in OCT-A Radial Peripapillary Capillary Plexus (RPCP) values to predict progression in the RNFL failed to show superiority in the superior, inferior, nasal, temporal and total quadrants (respectively p = 0,21,0,53,0,39,0,39, 0.29). The ability of the change in OCT-A RPCP values to predict progression in GA failed to show superiority in the superior, inferior, nasal, temporal, and total quadrants (p = 0.96,0.29,0,77,0.42, 0.21, respectively). DISCUSSION AND CONCLUSION: Although OCT-A is a non-invasive imaging test whose use and popularity have been increasing in recent years; In our study could not show superiority compared to RNFL and GA tests in demonstrating glaucoma progression.
Publisher
Research Square Platform LLC